What is the recommendation for Glaxines's Valuation of Briodal? Glaxine's executives are concerned that if Briodal were to be approved by the FDA and become available for sale, their product's market share (Xenor's market share) would be negatively affected. To maintain Xenor's market share, Glaxine's executives want to purchase the rights to Briodal so that they can discontinue Briodal's development. For purposes of performing their discounted cash flow analysis, Glaxine's executives used a 20?
